• Home
  • News
  • Portfolio News
  • Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials

Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials

21Jul

Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials

Portfolio News

Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $1,700,000 Small Business Innovation Research (SBIR) grant to advance Zylö’s proprietary nitric-oxide-releasing topical drug candidate into clinical trials. Read more >>

Share this post

Related Posts

22Dec

Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model

Hoth has a partnership agreement with Zylö Therapeutics Inc., to co-develop a new topical treatment for patients with Cutaneous Lupus... read more
16Apr

eSight wearable technology to aid blind veterans in seeing

This new tech was created to help improve the vision of veterans who are legally blind. eSight, a firm that... read more
13Feb

Carbonite to Present at Upcoming Investor Conferences

Carbonite, Inc., a global leader in data protection, today announced that the company is scheduled to participate at the following... read more
10Oct

Marketing enters its digital renaissance

A major movement as part of the Renaissance era, Humanism is defined by scholars as an intellectual movement in which... read more
13Nov

Carbonite To Be Acquired by OpenText for $1.42 Billion

Data protection and cybersecurity solution provider, Carbonite, has announced it has entered a definitive agreement to be acquired by OpenText.... read more
08Sep

Myomo, Inc. Announces Granting of Patents in China and Hong Kong

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,... read more
27Apr

US fishmeal substitute player inks process collaboration deal

KnipBio and ICM have agreed a joint effort to work on a commercial-scale fermentation process for the biotech company's premium... read more
18Aug

Noninvasive Respiratory Volume Monitoring Effective for Nonintubated Colonoscopy Patients

The monitor—ExSpiron (Respiratory Motion Inc.)—provides continuous monitoring of minute ventilation, tidal volume and respiratory rate. The monitor has a sensor... read more
28Jan

Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a clinical-stage cell therapy company dedicated to improving the lives... read more
27Aug

1,298 VA centers nationwide to get Sight Enhancing Medical Devices

Leading vision-enhancement platform, eSight™, and Marathon Medical Corporation, an SDVOSB (Service-Disabled Veteran Owned Small Business) certified distributor to veteran medical... read more